

RESEARCH LETTER

Open Access



Rate control in atrial fibrillation using Landiolol is safe in critically ill Covid-19 patients

Geoffroy Hariri^{1,2}, Tomas Urbina^{1,2}, Sandie Mazerand¹, Naïke Bige¹, Jean-Luc Baudel¹ and Hafid Ait-Oufella^{1,2,3*} 

Dear editor,

Atrial fibrillation (AF) is frequent in shock patients admitted to the intensive care unit (ICU) [1, 2] and is associated with increased mortality [1]. Several mechanisms are involved in the development of AF in the context of acute circulatory failure, including hypovolemia and β 1-adrenergic stimulation in response to endogenous catecholamine production as well as norepinephrine infusion [3]. Atrial fibrillation impairs left ventricular filling and consecutively stroke volume, and in fine potentially aggravates circulatory failure.

Pharmacological options to control AF-related tachycardia are limited. Calcium channel blockers are not frequently used because of long-term negative inotropic effects. Amiodarone is the most used drug but its optimal dosage to fine tune heart rate remains an issue, as well as its potential lung toxicity, especially in case of acute respiratory disease. Landiolol is a beta-blocker with highly β 1 selective activity, used either in AF patients either to control heart rate or to prevent supraventricular arrhythmia occurrence in the context of cardiac surgery. Landiolol has an ultrashort half-life of 4 min and weaker negative inotropic effect compared with other intravenous β -blockers [4]. A recent randomized controlled trial in patient with sepsis/septic shock developing tachyarrhythmia showed that Landiolol infusion efficiently reduced heart rate without any significant hemodynamic side effect [5].

Here, we described in critically ill patients admitted to the ICU for SARS-CoV-2 infections presenting with AF, our experience of Landiolol use in terms of efficacy and safety.

Methods

In our 18-bed intensive care unit, we prospectively collected data from adult patients admitted for SARS-CoV-2 infections with persistent AF. When heart rate was over 120 bpm, Landiolol was started at a minimum dose of 0.2 μ g/kg/min and progressively increased by steps of 0.2–0.4 μ g/kg/min every hour to achieve 20% reduction in heart rate, without bolus. Hemodynamic parameters were recorded every 2 h during the first 24 h of drug infusion.

Results

Fifteen consecutive patients with SARS-CoV-2 infection were treated with Landiolol during a 6-month period. Median age was 70 [67–72] years old, 27% were female, and median SOFA score was 11 [7–12]. Six patients (6/15, 40%) had a history of chronic AF, and the other had recent AF resistant to electric cardioversion. Median left ventricular (LV) function was 55% [50–57] (Table 1) and no patient had LV ejection fraction <40%. All included patients underwent invasive mechanical ventilation support and eleven (11/15, 73%) required norepinephrine. Median time between ICU admission and Landiolol initiation was 2 [0–5] days. Landiolol infusion was started at 0.2 μ g/kg/min and dosage reached 3.9 [1.6–7.0] μ g/kg/min at 24 h. Overall heart rate reduction was 23% (115 [108–117] vs 150 [138–160] bpm; $p < 0.01$, Wilcoxon signed-rank test), without any negative impact on global hemodynamic or tissue perfusion parameters (Table 1).

*Correspondence: hafid.aitoufella@aphp.fr

¹ Service de réanimation médicale, Assistance Publique – Hôpitaux de Paris (AP-HP), Hôpital Saint-Antoine, 184 Rue du Faubourg Saint-Antoine, 75571 Paris Cedex 12, France

Full list of author information is available at the end of the article



Table 1 Global hemodynamic and tissue perfusion parameters before and after (H24) Landiolol initiation

Patient characteristics		n = 15	
Age (years old)		70 [67–72]	
Women, n (%)		4 (27)	
SOFA		11 [7–12]	
Left ventricular ejection fraction (LVEF) (%)		55 [50–57]	
LVEF ≥ 60% (n)		4/15	
LVEF ≥ 50% and < 60% (n)		8/15	
LVEF ≥ 40% and < 50% (n)		3/15	
Time between ICU admission and injection (days)		2 [0–5]	
Comorbidities, n (%)			
Arterial hypertension		8 (53)	
Diabetes mellitus		4 (27)	
Vascular disease		5 (33)	
Norepinephrine, n (%)		11 (73)	
Mechanical ventilation, n (%)		15 (100)	
Hemodynamic kinetics	H0	H24	p
Global hemodynamics			
Heart rate (bpm)	150 [138–160]	115 [108–117]	< 0.01
Systolic blood pressure (mmHg)	115 [99–130]	120 [108–125]	0.70
Diastolic blood pressure (mmHg)	58 [51–74]	60 [53–66]	0.71
Mean arterial pressure (mmHg)	79 [69–89]	76 [72–88]	0.76
Norepinephrine dose (µg/kg/min)	1 [0.4–1.5]	0.7 [0.2–1]	0.04
Tissue perfusion parameters			
Index capillary refill time (s)	2 [1.5–2.5]	2 [1.6–2.5]	0.75
Mottling score n (%)			0.62
0–1	12 (80)	13 (87)	
2–3	1 (7)	2 (13)	
> 4	2 (13)	0 (0)	
Arterial lactate level (mmol/L)	3.2 [2–4.9]	2.2 [1.7–2.8]	0.05

Interestingly, during Landiolol infusion, norepinephrine need decreased in 9/11 patients (81%), and mean norepinephrine dose significantly decreased (0.7 [0.2–1] vs 1 [0.4–1.5] µg/kg/min; $p = 0.04$, Wilcoxon signed-rank test) (Fig. 1).

Discussion

In this observational uncontrolled study, Landiolol was safely used to lower heart rate in critically ill patients with AF with normal or moderately altered cardiac function. Given that most patients under mechanical ventilation for SARS-CoV-2 infections received norepinephrine and that some of them had moderate left ventricular systolic function, Landiolol infusion was started at very low doses and maximal infusion rate at 24 h was lower than reported in studies on non-critically ill patients [6]. Using this protocol, hemodynamic tolerance was excellent without any significant arterial hypotension or alteration in peripheral tissue perfusion. Moreover, we observed

a decrease in norepinephrine need after Landiolol initiation. Additional studies are required to investigate the potential beneficial mechanisms of Landiolol on global hemodynamics.

Acknowledgements

Not applicable.

Authors' contribution

Study concept and design, all authors. Acquisitions of data, G.H., T.U. and H.A.O. Drafting of the manuscript, G.H., T.U., H.A.O. Critical revision of manuscript, all authors. Statistical analysis, G.H. and H.A.O. All authors read and approved the final manuscript.

Funding


None.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

Not applicable for monocenter observational study.



Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests. H.A.O. declares having received fees for medical trainings from the laboratories AMOMED.

Author details

¹ Service de réanimation médicale, Assistance Publique – Hôpitaux de Paris (AP-HP), Hôpital Saint-Antoine, 184 Rue du Faubourg Saint-Antoine, 75571 Paris Cedex 12, France. ² Sorbonne Université, Paris, France. ³ Inserm U970, Centre de Recherche Cardiovasculaire de Paris (PARCC), Paris, France.

Received: 28 December 2020 Accepted: 13 January 2021

Published online: 22 January 2021

References

- Steinberg I, Brogi E, Pratali L, Trunfio D, Giuliano G, Bignami E, Forfori F. Atrial fibrillation in patients with septic shock: a one-year observational pilot study. *Turk J Anaesthesiol Reanim.* 2019;47(3):213–9.
- Meierhenrich R, Steinhilber E, Eggermann C, Weiss M, Voglic S, Bogelein D, Gauss A, et al. Incidence and prognostic impact of new-onset atrial

fibrillation in patients with septic shock: a prospective observational study. *Crit Care.* 2010;14(3):R108.

- Schmittinger CA, Torgersen C, Luckner G, Schroder DC, Lorenz I, Dunser MW. Adverse cardiac events during catecholamine vasopressor therapy: a prospective observational study. *Intensive Care Med.* 2012;38(6):950–8.
- Sasao J, Tarver SD, Kindscher JD, Taneyama C, Benson KT, Goto H. In rabbits, landiolol, a new ultra-short-acting beta-blocker, exerts a more potent negative chronotropic effect and less effect on blood pressure than esmolol. *Can J Anaesth.* 2001;48(10):985–9.
- Kakihana Y, Nishida O, Taniguchi T, Okajima M, Morimatsu H, Ogura H, Yamada Y, et al. Efficacy and safety of landiolol, an ultra-short-acting beta1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial. *Lancet Respir Med.* 2020;9:863–72.
- Matsuishi Y, Mathis BJ, Shimojo N, Kawano S, Inoue Y. Evaluating the therapeutic efficacy and safety of landiolol hydrochloride for management of arrhythmia in critical settings: review of the literature. *Vasc Health Risk Manag.* 2020;16:111–23.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.